Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
More Reading from MarketBeat
The Often-Missed Corner of Healthcare That Wall Street Is LovingBy Nathan Reiff. Date Posted: 3/29/2026. 
Key Points
- Numerous lab equipment stocks are down in the high-teens so far this year, but seemingly modest sales growth may hide fundamental strengths.
- These companies can present a more secure approach to the healthcare industry than some higher-risk alternatives.
- Still, headwinds including tariff impacts and inflation remain a concern.
- Special Report: Elon Musk already made me a “wealthy man”
The healthcare industry is notoriously volatile—company fortunes can be made or broken on the success of a single product or the results of a clinical trial—and it's not uncommon for stocks in this sector to experience some of the market's wildest spikes and drops. Investors who want exposure to the healthcare space but are wary of that turbulence may prefer a "picks and shovels" approach that focuses on companies providing essential equipment and services rather than higher-risk pharmaceutical names. Lab equipment stocks are often overlooked by investors, even though some companies in this subindustry rank among the largest in healthcare. With several external factors likely to affect healthcare companies in 2026—shifting subsidies, an aging population, inflation, the growing role of AI, and more—core lab-equipment businesses may be particularly attractive. The companies below are some of the major players investors should consider. A Recent Dip Masks Thermo Fisher's Long-Term Strengths
Whitney Tilson - the Wall Street analyst who called the 2000 dot-com collapse and appeared on an Emmy-winning 60 Minutes segment covering the 2008 financial crisis - is issuing what he calls his most urgent warning yet.
Tilson says the next six months will bring extreme change for millions of Americans, and he's outlined specific steps to protect your money - moves he believes could outperform stocks, bonds, and gold. Access Tilson's full preparation plan here, free of charge
The $182 billion life-sciences solutions, diagnostics, and analytical-instruments company Thermo Fisher Scientific (NYSE: TMO) has had a difficult start to 2026, with shares down more than 15% year-to-date (YTD). The stock recently fell into TradeSmith's red zone for financial health. Much of the recent weakness appears tied to tariffs and foreign-exchange (FX) volatility, which together pressured margins by more than 100 basis points in 2025. There are, however, bright spots in Thermo Fisher's recent performance. In Q4 2025, revenue was $12.2 billion, up 7% year-over-year (YOY) and about $250 million above analyst estimates. Adjusted earnings per share (EPS) also exceeded expectations at $6.57. That momentum may reflect several recent product introductions, including the Orbitrap Astral Zoom mass spectrometer and new bioreactor products. Thermo Fisher's broad business model and diversified product portfolio could help it absorb external pressures. Even if 2026 guidance is modest, with revenue projected to grow 4% to 6%, improvements in EBITDA margin are a positive. Persistent customer demand and product momentum likely support optimism: 17 of 19 analysts rate the stock a Buy or equivalent, and consensus estimates imply more than 29% upside. Danaher's Business May Be Improving, Even as Guidance Remains ModestDanaher Corp. (NYSE: DHR) shares are down nearly 20% YTD, putting it in a similar position to Thermo Fisher. While 2026 guidance points to modest core revenue growth of 3% to 6% YOY, the latest quarter included both a top- and bottom-line beat and generated $5.3 billion in free cash flow for 2025. Two areas to watch in 2026 are Danaher's bioprocessing business, expected to deliver high-single-digit revenue growth driven by strong monoclonal antibody demand, and its diagnostics segment. Diagnostics should benefit from recent FDA clearances. Additionally, equipment orders have begun to improve after a prolonged weak period, which could help sales recover. Analysts are moderately bullish on DHR, forecasting about 12.3% earnings growth over the next year and roughly 35% potential share-price appreciation. That outlook helps explain why 19 of 22 ratings on the stock are Buys. Agilent's Biocare Purchase Could Be a CatalystAgilent Technologies (NYSE: A) has shown slower momentum than the companies above. Its latest results reported 4.4% YOY revenue growth and marginal misses on both revenue and earnings versus analyst expectations. Agilent's recent acquisition of Biocare Medical, however, could be a meaningful growth catalyst by strengthening its position in cancer diagnostics. The nearly $1 billion purchase should add a recurring-revenue stream in a high-demand area and could be higher margin than some of Agilent's existing lines, potentially supporting operating-margin improvement (the company's operating margin was 24.6% last quarter). Despite a roughly 17% YTD decline, analysts see significant upside: consensus estimates point to about 42% potential appreciation. Wall Street rates the stock a Moderate Buy overall, with 13 of 16 analysts issuing Buy or similar ratings. |
